Get the Stockscreener App
13.55
1.74%
-0.24
Pre-market:
13.55
Ars Pharmaceuticals Inc stock is traded at $13.55, with a volume of 1.13M.
It is down -1.74% in the last 24 hours and down -15.26% over the past month.
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the development of novel, potentially first-in-class product candidate, neffy for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows neffy to provide injection-like absorption of epinephrine at a low dose, in a small, easy-to-carry, easy-to-use, rapidly administered and reliable nasal spray.
See More
Previous Close:
$13.79
Open:
$13.61
24h Volume:
1.13M
Relative Volume:
0.98
Market Cap:
$1.32B
Revenue:
-
Net Income/Loss:
$-44.84M
P/E Ratio:
-27.89
EPS:
-0.4858
Net Cash Flow:
$-44.23M
1W Performance:
-3.76%
1M Performance:
-15.26%
6M Performance:
+47.44%
1Y Performance:
+183.47%
1-Day Range:
$13.15
$13.87
1-Week Range:
$13.15
$15.25
52-Week Range:
$4.64
$18.51
Ars Pharmaceuticals Inc Stock (SPRY) Company Profile
Name
Ars Pharmaceuticals Inc
Sector
Industry
Phone
858-771-9307
Address
11682 EL CAMINO REAL, SUITE 120, SAN DIEGO
Compare SPRY with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| SPRY | 13.55 | 1.32B | 0 | -44.84M | -44.23M | -0.4858 |
| VRTX | 451.23 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 743.35 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 591.82 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 248.79 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 102.14 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Ars Pharmaceuticals Inc Stock (SPRY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-31-23 | Initiated | Wedbush | Outperform |
| Jan-03-23 | Initiated | William Blair | Outperform |
| Dec-13-22 | Initiated | SVB Leerink | Outperform |
Ars Pharmaceuticals Inc Stock (SPRY) Latest News
ARS Pharmaceuticals: Demand Curve Is Key Unknown (NASDAQ:SPRY) - Seeking Alpha
ARS Pharmaceuticals, Inc. (SPRY) Reports Q3 Loss, Misses Revenue Estimates - MSN
First Turn Management LLC Takes Position in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) - MarketBeat
What is William Blair's Forecast for SPRY FY2024 Earnings? - MarketBeat
FY2024 Earnings Forecast for SPRY Issued By Leerink Partnrs - MarketBeat
Emily Leonard - Global Legal Chronicle
Oliver Hodgkiss - Global Legal Chronicle
ALK’s Licensing Agreement with ARS Pharmaceuticals - Global Legal Chronicle
Royce & Associates LP Acquires 45,755 Shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) - MarketBeat
(SPRY) On The My Stocks Page - Stock Traders Daily
What is Leerink Partnrs' Estimate for SPRY FY2027 Earnings? - MarketBeat
Q4 EPS Estimate for ARS Pharmaceuticals Boosted by Analyst - MarketBeat
Loss-Making ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Expected To Breakeven In The Medium-Term - Yahoo Finance
NEURELIS ENTERS $208 MILLION AGREEMENT TO MONETIZE INTRAVAIL ROYALTIES - PR Newswire
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Q3 2024 Earnings Call Transcript - Insider Monkey
GSA Capital Partners LLP Purchases 39,921 Shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) - MarketBeat
ARS Pharmaceuticals earnings missed by $0.06, revenue topped estimates - Investing.com Canada
ARS Pharmaceuticals’ Strong Q3 2024 Highlights - TipRanks
Deerfield management sells ARS Pharmaceuticals shares for $10.14 million - Investing.com India
Deerfield management sells ARS Pharmaceuticals shares for $10.14 million By Investing.com - Investing.com Canada
ARS Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
ARS Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Updates - GlobeNewswire
ARS Pharma Launches Groundbreaking Needle-Free Epinephrine Spray, Secures $465M Deal | SPRY Stock News - StockTitan
Insights Ahead: ARS Pharmaceuticals's Quarterly Earnings - Benzinga
ARS Pharmaceuticals inks global deal for epinephrine product By Investing.com - Investing.com Canada
ARS Pharmaceuticals inks global deal for epinephrine product - Investing.com
ARS Pharmaceuticals announces agreement with ALK to commercialize neffy - Yahoo Finance
ARS Pharma Jumps After Inking $145 Million Deal For Epinephrine Nasal Spray - Yahoo! Voices
ALK snags EU and Canada rights to anaphylaxis nasal spray Neffy for $145m - Yahoo Finance
ARS Pharmaceuticals (NASDAQ:SPRY) Sets New 52-Week HighTime to Buy? - MarketBeat
ARS Pharmaceuticals Inks Licensing Pact For Neffy Allergic Reaction Treatment, Analyst Sees Further Stock Upside Despite 200% Surge In 2024 - Yahoo Finance
ARS Pharmaceuticals Announces Exclusive Agreement with Global Allergy Leader ALK to Commercialize neffy® in Europe, Canada and Other Geographies Outside the United States - GlobeNewswire
ARS Pharma Lands $465M Global Deal for Needle-Free Allergy Drug neffy® | SPRY Stock News - StockTitan
Wall Street Analysts Think ARS Pharmaceuticals, Inc. (SPRY) Could Surge 67.56%: Read This Before Placing a Bet - MSN
ALK licenses rights to neffy®, the first approved adrenaline nasal spray for emergency treatment of allergic reactions (anaphylaxis) - The Manila Times
Amazon.com Inc (AMZN-Q) QuotePress Release - The Globe and Mail
ARS Pharmaceuticals (SPRY) Set to Announce Quarterly Earnings on Wednesday - MarketBeat
Institutional investors control 35% of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) and were rewarded last week after stock increased 10% - Simply Wall St
The Physician-Patient Alliance for Health & Safety Expands Board of Advisors with Five Healthcare Industry Leaders, Enhancing Commitment to Patient Safety and Innovation - GlobeNewswire Inc.
ARS Pharmaceuticals Announces Conference Call and Webcasts - GlobeNewswire
ARS Pharmaceuticals Sets Q3 Earnings Call, Plans Major Healthcare Conference Tour | SPRY Stock News - StockTitan
William Blair Has Positive Forecast for SPRY FY2024 Earnings - MarketBeat
ARS Pharmaceuticals Announces Conference Call and Webcasts for its Third Quarter 2024 Financial Results and Presentations at Upcoming Conferences - Yahoo Finance
(SPRY) Pivots Trading Plans and Risk Controls - Stock Traders Daily
Raymond James & Associates Invests $2.97 Million in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) - MarketBeat
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Receives $24.00 Consensus Target Price from Brokerages - MarketBeat
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Given Average Recommendation of “Buy” by Analysts - Defense World
Here's Why 'Trend' Investors Would Love Betting on ARS Pharmaceuticals, Inc. (SPRY) - MSN
Allspring Global Investments Holdings LLC Invests $2.58 Million in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) - MarketBeat
ARS Pharmaceuticals shares a new treatment for allergic reactions - KATV
New Data on Needle Free Epinephrine Spray Presented at ACAAI 2024 - Patient Care Online
Ars Pharmaceuticals Inc Stock (SPRY) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.69%
6.90%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):